Correlation of BMI-1 and ROR1 expression with clinical and morphological parameters and the course of luminal breast cancer
https://doi.org/10.31549/2542-1174-2024-8-1-88-99
Abstract
Introduction. Luminal breast cancer (BC) occupies the largest proportion in the structure of the entire molecular landscape of this disease. During the ongoing treatment, most often hormone therapy, in part of patients, the disease progression develops, which makes necessary the search for new molecular predictors.
Aim of the research. To study the clinical and morphological features of the disease depending on BMI-1 and ROR1 expression in the primary tumor in luminal breast cancer patients during aromatase inhibitors therapy.
Materials and methods. The study included 80 patients with T1-2N0-1M0 operable primary breast cancer at the age of 62.1 ± 8.1 years. The primary tumor tissue was studied using immunohistochemistry. Antibodies to ROR1 and BMI-1 were used. The presence and degree of immunostaining, and the percentage of positively stained tumor cells were assessed. The expression parameters of the studied markers were assessed in relation to various clinical and pathological data of the disease.
Results. 70 patients had the luminal A subtype, 10 patients had the luminal B/HER2-negative subtype. Positive BMI-1 expression was observed in 64% of cases, ROR1 expression was less common and amounted to 24%. As tumor grade increases, the number of cases with positive ROR1 expression increases ( p < 0.05). The level of proliferative activity (Ki67) correlated with positive ROR1 expression ( ρ = 0.312, p = 0.03) and BMI-1 ( ρ = 0.310, p < 0.031). In presence of metastases to regional lymph nodes, the expression of both markers was significantly higher. The occurrence of distant metastases is associated with high levels of BMI-1 expression by primary tumor cells ( p < 0.05).
Conclusion. The study clearly demonstrates the correlation of ROR1 and BMI-1 proteins with the clinical and morphological parameters of the primary tumor and the course of the disease in luminal subtypes of breast cancer.
About the Authors
V. О. Tarakanova
Cancer Research Institute, Tomsk National Research Medical Center, Russian Academy of Sciences; Siberian State Medical University
Russian Federation
Russian Federation
Valeriia O. Tarakanova – Junior Researcher; Assistant, Department of Oncology
Scopus Author ID: 869234
5, Kooperativny str., Tomsk, 634009
N. V. Krakhmal’
Cancer Research Institute, Tomsk National Research Medical Center, Russian Academy of Sciences; Siberian State Medical University
Russian Federation
Russian Federation
Nadezhda V. Krakhmal’ – Cand. Sci. (Med.), Associate Professor, Senior Researcher, Department of General and Molecular Pathology; Associate Professor, Department of Pathological Anatomy
Researcher ID: S-3799-2016
Scopus Author ID: 56678622400
5, Kooperativny str., Tomsk, 634009
N. N. Babyshkina
Cancer Research Institute, Tomsk National Research Medical Center, Russian Academy of Sciences; Siberian State Medical University
Russian Federation
Russian Federation
Nataliya N. Babyshkina – Dr. Sci. (Med.), Senior Researcher, Laboratory of Molecular Oncology and Immunology; Associate Professor, Department of Biochemistry and Molecular Biology with a course of Laboratory Diagnostics
Scopus Author ID: 26641099700
Researcher ID: A-7526-2012
5, Kooperativny str., Tomsk, 634009
S. V. Vtorushin
Cancer Research Institute, Tomsk National Research Medical Center, Russian Academy of Sciences; Siberian State Medical University
Russian Federation
Russian Federation
Sergey V. Vtorushin – Dr. Sci. (Med.), Head, Department of General and Molecular Pathology; Professor, Department of Pathological Anatomy
Researcher ID: S-3789-2016
Scopus Author ID: 26654562300
5, Kooperativny str., Tomsk, 634009
References
1. Liu Y., Yang H., Chen T. et al. Silencing of receptor tyrosine kinase ROR1 inhibits tumor-cell proliferation via PI3K/AKT/mTOR signaling pathway in lung adenocarcinoma // PloS one. 2015;10(5):e0127092. DOI: 10.1371/journal.pone.0127092.
2. Chien H.P., Ueng S.H., Chen S.C. et al. Expression of ROR1 has prognostic significance in triple negative breast cancer // Virchows Archiv. 2016;468(5):589-595. DOI: 10.1007/s00428-016-1911-3.
3. Zhang S., Cui B., Lai H. et al. Ovarian cancer stem cells express ROR1, which can be targeted for anticancer-stem-cell therapy // Proc. Nat. Acad. Sci. USA. 2014;111(48):17266-17271. DOI: 10.1073/pnas.1419599111.
4. Dave H., Anver M.R., Butcher D.O. et al. Restricted cell surface expression of receptor tyrosine kinase ROR1 in pediatric B-lineage acute lymphoblastic leukemia suggests targetability with therapeutic monoclonal antibodies // PloS One. 2012;7(12):e52655. DOI: 10.1371/journal.pone.0052655.
5. Hamilton G., Rath B., Klameth L., Hochmair M. Receptor tyrosine kinase expression of circulating tumor cells in small cell lung cancer // Oncoscience. 2015;2(7):629-634. DOI: 10.18632/oncoscience.179.
6. Karachaliou N., Gimenez-Capitan A., Drozdowskyj A. et al. ROR1 as a novel therapeutic target for EGFR-mutant non-small-cell lung cancer patients with the EGFR T790M mutation // Transl. Lung Cancer Res. 2014;3(3):122-130. DOI: 10.3978/j.issn.2218-6751.2014.03.02.
7. Hudecek M., Schmitt T.M., Baskar S. et al. The B-cell tumor-associated antigen ROR1 can be targeted with T cells modified to express a ROR1-specific chimeric antigen receptor // Blood. 2010;116(22):4532-4541. DOI: 10.1182/blood-2010-05-283309.
8. Baskar S., Kwong K.Y., Hofer T. et al. Unique cell surface expression of receptor tyrosine kinase ROR1 in human B-cell chronic lymphocytic leukemia // Clin. Cancer Res. 2008;14(2):396-404. DOI: 10.1158/1078-0432.CCR-07-1823.
9. Balakrishnan A., Goodpaster T., Randolph-Habecker J. et al. Analysis of ROR1 protein expression in human cancer and normal tissues // Clin. Cancer Res. 2017;23(12):3061-3071. DOI: 10.1158/1078-0432.CCR-16-2083.
10. Li C., Wang S., Xing Z. et al. A ROR1-HER3-lncRNA signalling axis modulates the Hippo-YAP pathway to regulate bone metastasis // Nat. Cell Biol. 2017;19(2):106-119. DOI: 10.1038/ncb3464.
11. Pandey G., Borcherding N., Kolb R. et al. ROR1 potentiates FGFR signaling in basal-like breast cancer // Cancers (Basel). 2019;11(5):718. DOI: 10.3390/cancers11050718.
12. Hasan M.K., Widhopf G.F. 2nd, Zhang S. et al. Wnt5a induces ROR1 to recruit cortactin to promote breast-cancer migration and metastasis // NPJ Breast Cancer. 2019;5:35. DOI: 10.1038/s41523-019-0131-9.
13. Bhattacharya R., Mustafi S.B., Street M. et al. Bmi-1: At the crossroads of physiological and pathological biology // Genes Dis. 2015;2(3):225-239. DOI: 10.1016/j.gendis.2015.04.001.
14. Liu Y., Liu F., Yu H. et al. Akt phosphorylates the transcriptional repressor Bmi1 to block its effects on the tumor-suppressing INK4a-ARF locus // Sci Signal. 2012;5(247):ra77. DOI: 10.1126/scisignal.2003199.
15. Guo B.H., Feng Y., Zhang R. et al. Bmi-1 promotes invasion and metastasis, and its elevated expression is correlated with an advanced stage of breast cancer // Mol. Cancer. 2011;10(1):10. DOI: 10.1186/1476-4598-10-10.
16. Liu J.Y., Jiang Y.N., Huang H. et al. BMI-1 promotes breast cancer proliferation and metastasis through different mechanisms in different subtypes // Cancer Sci. 2023;114(2):449-462. DOI: 10.1111/cas.15623.
17. Kim W.Y., Sharpless N.E. The regulation of INK4/ARF in cancer and aging // Cell. 2006;127(2):265-275. DOI: 10.1016/j.cell.2006.10.003.
18. Wang Y., Jin W., Jia X. et al. Transcriptional repression of CDKN2D by PML/RAR α contributes to the altered proliferation and differentiation block of acute promyelocytic leukemia cells // Cell Death Dis. 2014;5(10):e1431. DOI: 10.1038/cddis.2014.388.
19. Garcia-Recio S., Thennavan A., East M.P. et al. FGFR4 regulates tumor subtype differentiation in luminal breast cancer and metastatic disease // J. Clin. Invest. 2020;130(9):4871-4887. DOI: 10.1172/JCI130323.
Review
For citations:
Tarakanova V.О., Krakhmal’ N.V., Babyshkina N.N., Vtorushin S.V. Correlation of BMI-1 and ROR1 expression with clinical and morphological parameters and the course of luminal breast cancer. Journal of Siberian Medical Sciences. 2024;(1):88-99. (In Russ.) https://doi.org/10.31549/2542-1174-2024-8-1-88-99
Views:
109
Email this article 